Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer

IMPORTANCE: The most useful biomarkers for clinical decision-making identify patients likely to have improved outcomes with one treatment vs another. OBJECTIVE: To evaluate treatment class-specific outcomes of patients receiving immune checkpoint inhibitor (ICI) vs taxane chemotherapy by tumor mutat...

Descripción completa

Detalles Bibliográficos
Autores principales: Graf, Ryon P., Fisher, Virginia, Weberpals, Janick, Gjoerup, Ole, Tierno, Marni B., Huang, Richard S. P., Sayegh, Nicolas, Lin, Douglas I., Raskina, Kira, Schrock, Alexa B., Severson, Eric, Haberberger, James F., Ross, Jeffrey S., Creeden, James, Levy, Mia A., Alexander, Brian M., Oxnard, Geoffrey R., Agarwal, Neeraj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972027/
https://www.ncbi.nlm.nih.gov/pubmed/35357449
http://dx.doi.org/10.1001/jamanetworkopen.2022.5394

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972027/
https://www.ncbi.nlm.nih.gov/pubmed/35357449
http://dx.doi.org/10.1001/jamanetworkopen.2022.5394

Ejemplares similares